title: [Myocardial regeneration: proliferative potential of cardiomyocytes and induction of cardiomyogenesis in alterative and plastic cardiac failure].
abstract: The authors present data on the character and manifestations of regenerative reactions of cardiomyocytes at alterative and plastic cardiac failure, propose morphological criteria for the assessment of cardiomyocyte regenerative potential, and consider the possibility to induce cellular forms of cardiomyocyte regeneration in patients with cardiomyopathies and in the post-infarction period. The quantitative morphological study showed that absolute number of cardiomyocytes and the ratio of their mono- to binuclear forms are the most informative criteria of regeneration of these cells affected by cytotoxic and biologically active agents. Populations of mononuclear cardiomyocytes are believed to play the key role in the maintenance of myocardium regenerative capacity. Morphological equivalents of cardiomyocyte proliferative activity and main forms of regeneration of muscular fibers exposed to cytotoxic factors are described. Studies on induction of myocardial regenerative reactions in the post-infarction period revealed major morphogenetic effects of endothelial growth factor and mononuclear marrow cells implanted in the myocardium.
authors.forename: L M
authors.initials: LM
authors.lastname: Nepomniashchikh
authors.forename: E L
authors.initials: EL
authors.lastname: Lushnikova
authors.forename: P M
authors.initials: PM
authors.lastname: Larionov
authors.forename: M G
authors.initials: MG
authors.lastname: Shurygin
mesh_terms: D000818:Animals; D017209:Apoptosis; D016026:Bone Marrow Transplantation; D002452:Cell Count; D002454:Cell Differentiation; D049109:Cell Proliferation; D003520:Cyclophosphamide / Q000494:pharmacology; D054697:Cytostatic Agents / Q000494:pharmacology; D004195:Disease Models, Animal; D004285:Dogs; D004317:Doxorubicin / Q000494:pharmacology; D006333:Heart Failure / Q000473:pathology*; D009203:Myocardial Infarction / Q000473:pathology / Q000628:therapy; D009206:Myocardium / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology* / Q000502:physiology; D018919:Neovascularization, Physiologic; D051381:Rats; D012038:Regeneration; D042461:Vascular Endothelial Growth Factor A / Q000494:pharmacology / Q000502:physiology
chemical_list: D054697:Cytostatic Agents; D042461:Vascular Endothelial Growth Factor A; D004317:Doxorubicin; D003520:Cyclophosphamide